Biocon Biologics Ltd. will unveil three new biosimilar oncology assets at the 2026 J.P. Morgan Healthcare Conference, including proposed biosimilars of Herceptin, Opdivo, and Keytruda. The company will also outline its planned integration into Biocon Ltd. as a wholly owned subsidiary, strengthening its global leadership in biosimilars and diabetes care.
Biocon Biologics Ltd. (BBL), a global biosimilars leader and subsidiary of Biocon Ltd., announced the expansion of its oncology portfolio with three proposed biosimilars—Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin Hylecta), Nivolumab (Opdivo), and Pembrolizumab (Keytruda). The announcement will be detailed at the 44th J.P. Morgan Healthcare Conference in San Francisco.
The company’s oncology pipeline now includes two PD‑1 inhibitors, positioning BBL among the few global players with a broad spectrum of biosimilar oncology assets. Combined with its recent FDA submission for Pertuzumab (Perjeta), the portfolio represents a $75 billion global market opportunity.
Key Highlights
-
Three new oncology biosimilars to expand cancer care access and affordability
-
Integration into Biocon Ltd. as a wholly owned subsidiary by March 2026
-
Unified business to lead in biosimilars and GLP‑1 generics across diabetes, oncology, and immunology
-
Over 6 million patients served in 120+ markets
-
Shreehas Tambe to present the company’s vision at the J.P. Morgan Healthcare Conference and Endpoints at JPM26 event
Source: Biocon Biologics Ltd. press release, J.P. Morgan Healthcare Conference 2026 website, Endpoints News